Singapore Expedited versus Abridged Registration Routes Compared

1. Key takeaways

Both the Expedited and Abridged routes presuppose Reference Agency approvals; they differ in the applicable risk classes, the fees and the evaluation timelines. The Abridged route covers all classes, B/C/D, while the Expedited route mainly targets Class C/D. Taking Class C as an example: Abridged costs SGD 3,900 over 160 working days, while Expedited costs SGD 3,340 over 120 working days; for Class D, Abridged costs SGD 6,250 over 220 working days and Expedited SGD 5,930 over 180 working days.

• For Class C and Class D, Expedited beats Abridged on both fee and timeline, an unusual feature of the Singapore design that reflects a heavier reliance on Reference Agency evaluations.
• Because that reliance is heavier, Expedited eligibility conditions are stricter, and the route is not simply a matter of choice.
• Class B has no Expedited option at all: the choice is Immediate if eligible, otherwise Abridged or Full.
• Under both routes, the preclinical and clinical chapters may be submitted in summary form citing the Reference Agency conclusions, which is a real saving in dossier workload.
• Labeling differences must be compared and disclosed up front under Annex 4 Part 1, because excessive differences can undermine the reliance eligibility itself.

2. Legal basis

The routes and their eligibility rules are set out in GN-15 sections 4 to 6, and the fees and processing times below are taken from the official HSA fees and processing times page, updated to 26 March 2026. A uniform application fee is charged on top of the evaluation fee for every submission, whichever route is selected.

The table below places the two routes side by side for each risk class, using the official fee and working-day figures.

3. Expert insights

Insight one: Expedited is both faster and cheaper than Abridged, but the threshold is higher.

The data show that for Class C and Class D, Expedited is superior to Abridged on both the fee and the timeline (Class C: 3,340 versus 3,900 SGD; 120 versus 160 working days). This is uncommon in regulatory design, where faster usually means more expensive. A reasonable explanation is that Expedited depends more heavily on Reference Agency approvals, so HSA’s own review workload is smaller. But this also means its eligibility conditions are stricter, and it is not a route you can simply choose at will.

Insight two: the shared premise of both routes is reliance on an existing evaluation.

For Abridged and Expedited alike, the logic is that HSA partially relies on the evaluation already completed by the Reference Agency. The whole design of the faster routes rests on this transfer of review effort: instead of re-examining the evidence from scratch, HSA leverages the scrutiny already performed by an agency it recognises. Both routes therefore require that the approval covers the same device and the same intended use, and a device classified by the Reference Agency as Class I or Class II exempt does not qualify, because such listings involve no substantive review that HSA could rely upon.

Insight three: Class B has no Expedited, only Immediate or Full.

The options for Class B are: if eligible, take Immediate (SGD 1,000, immediate upon submission); otherwise Abridged (SGD 2,010 / 100 working days) or Full (SGD 3,900 / 160 working days). When planning routes for Class B, the first priority is always to check Immediate eligibility, because the spread between the cheapest and the most expensive Class B option is nearly a factor of four and the fastest option removes the waiting period altogether.

Insight four: under Abridged and Expedited, the clinical and preclinical chapters can be submitted as summaries.

Under the HSA submission framework (GN-17 R5 / GN-18 R5, with the official text governing the specific chapter requirements), applicants on the Abridged or Expedited routes may submit the preclinical and clinical parts in summary form, citing the evaluation conclusions of the Reference Agency. This is a substantive benefit of these two routes in terms of dossier workload, not merely in approval speed: the summarised chapters remove the need to reproduce full study reports that HSA will not re-review anyway. The saving only holds, however, when the citations point precisely to the Reference Agency’s own conclusions, so the underlying approval documents must be accurate and complete.

4. Practical recommendations

• Assess Expedited eligibility first for Class C/D: it wins on both fee and time.
• Assess Immediate first for Class B: do not default to Abridged.
• Make full use of the summary submission facility: on the Abridged and Expedited routes the preclinical and clinical chapters need not be rebuilt in full, but the Reference Agency conclusions must be cited accurately.
• Compare labeling differences up front: Annex 4 Part 1 requires disclosure of differences, and excessive differences can affect reliance eligibility.
• Turn the fee gap into a decision basis: Class D Abridged (6,250) and Full (12,000) differ by a factor of two, which justifies investing first in obtaining Reference Agency approvals.

5. Verification checklist

• □ The available routes for the product’s class have been confirmed
• □ Expedited eligibility has been assessed first for Class C/D
• □ The Reference Agency approval has been confirmed to cover the same device and the same intended use
• □ The Class I / Class II exempt scenarios of the Reference Agency have been excluded
• □ Summary-form clinical and preclinical chapters have been prepared
• □ The labeling difference comparison has been completed

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Singapore. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with HSA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com